Chimeric antigen receptors (CARs) against CD19 have been shown to direct T-cells to
specifically target B-lineage malignant cells in animal models and clinical trials, with efficient …

Introduction: Adoptive transfer of T cells expressing a CD19-specific chimeric antigen
receptor (CAR) has shown impressive response rates for the treatment of CD19+ B-cell …

Adoptive T-cell therapy with CD19-specific chimeric antigen receptors (CARs) is promising
for treatment of advanced B-cell malignancies. Tumor targeting of CAR-modified T-cells is …

Patients with refractory or recurrent B-lineage hematologic malignancies have less than
50% of chance of cure despite intensive therapy and innovative approaches are needed …

Chimeric antigen receptor (CAR)-based adoptive T-cell therapy is a highly promising
treatment for lymphoid malignancies, and CD20 is an ideal target antigen. We previously …

The ability to harness a patient's immune system to target malignant cells is now
transforming the treatment of many cancers, including hematologic malignancies. The …

Most B-cell malignancies express CD19, and a majority of patients with B-cell malignancies
are not cured by current standard therapies. Chimeric antigen receptors (CARs) are fusion …

T cells modified with CD19-specific chimeric antigen receptors (CARs) result in significant
clinical benefit for leukemia patients but constitute a challenge for manufacturing. We have …

Chimeric antigen receptors (CAR) combine an antigen-binding domain with a CD3-ζ
signaling motif to redirect T-cell specificity to clinically important targets. First-generation …

Cancer therapy with T cells expressing chimeric antigen receptors (CARs) has produced
remarkable clinical responses in recent trials, but also severe side effects. Whereas most …